Combination of | |
---|---|
Aliskiren | Renin inhibitor |
Amlodipine | Calcium channel blocker |
Hydrochlorothiazide | Diuretic |
Clinical data | |
Trade names | Amturnide |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
PubChem CID | |
KEGG |
|
Chemical and physical data | |
Formula | C57H86Cl2N8O15S2 |
Molar mass | 1258.38 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Aliskiren/amlodipine/hydrochlorothiazide, sold under the brand name Amturnide, is a fixed-dose combination medication that is used to treat high blood pressure.[1][2] It contains aliskiren, amlodipine, and hydrochlorothiazide.[1] It is taken by mouth.[1]
It was approved for medical use in the United States in December 2010.[1][3][4] Amturnide was withdrawn by Novartis from the US market in 2017.[5]
ACE inhibitors ("-pril") |
|
---|---|
AIIRAs ("-sartan") | |
Renin inhibitors ("-kiren") | |
Dual ACE/NEP inhibitors |
|
Neprilysin inhibitors | |
|
Sulfonamides (and etacrynic acid) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Potassium-sparing (at CD) |
| ||||||||
Osmotic diuretics (PT, DL) | |||||||||
Vasopressin receptor inhibitors (DCT and CD) | |||||||||
Other | |||||||||
Combination products | |||||||||
|